The global tax landscape is continuously transforming with increasingly complex regulatory changes and intense scrutiny of tax decisions by the public and regulatory authorities.

In Australia, the Australian Taxation Office has identified the Life Sciences (pharmaceutical and medical devices) sector as a key risk sector. Organisations in this sector face challenges in mitigating exposure to tax regulatory changes and in managing tax risk and governance in line with shifting expectations.

At KPMG, our team of industry-focused professionals utilises deep advisory and compliance expertise and an understanding of tax governance to assist businesses of all sizes from biotechnology startups to large multinational pharmaceutical companies. We provide long term support to our clients as they tackle challenges and transform the way healthcare is provided around the globe.

 

Webinar and video updates

Watch our short snapshot video from our tax specialist as well as the full presentations in our Life Sciences Tax Update webinar recording from 28 August 2019:

• Transfer Pricing: Latest guidance – Jeremy Capes